We Are Rewriting the Rules of Medicine
Ablatotech is building the world's most advanced living-medicine platform — engineered microorganisms that prevent and treat disease from inside the human body. Powered by artificial intelligence. Designed for every patient on Earth.
Medicine should reach every human being. We are making that possible.
Today, the most advanced therapies in medicine — immunotherapies, biologics, gene therapies — are available only to patients in wealthy countries with access to hospitals, intravenous infusion centers, cold-chain logistics, and six-figure treatment budgets. More than two billion people have access to none of these things.
Ablatotech is building a fundamentally different kind of medicine: oral, ambient-stable, manufactured at commodity scale, and effective against the most devastating diseases on Earth — from cancer to drug-resistant infections to diseases that have no treatment at all.
Our living-medicine platform turns beneficial microorganisms into programmable therapeutic agents. A single oral dose activates the body's own immune system to fight disease — no needles, no hospitals, no cold chain, no $100,000 price tags.
The Ablatotech Standard
Five Breakthroughs That Change Everything
Our innovations span the entire arc of medicine — from how drugs are discovered to how they are manufactured, delivered, and made available to every patient on Earth.
Living Medicine Platform
We engineer beneficial microorganisms — probiotic yeast, safe bacterial strains — to become precision therapeutic agents inside the human body. These living medicines navigate to disease sites, display therapeutic molecules on their surfaces, and activate the immune system with dual-pathway precision: both cellular (killer T cell) and mucosal (antibody) immunity from a single oral dose.
AI-Powered Drug Discovery
Our proprietary AI engine compresses years of drug discovery into days. It autonomously scans the world's biomedical literature, genomic databases, and clinical trial registries — identifying novel therapeutic targets, designing optimized constructs, predicting binding affinity and toxicity, and generating regulatory-ready documentation. All continuously, all autonomously.
Regional Multi-Target Strategy
Rather than building one drug for one disease, we engineer single organisms that target all diseases in a body region or all pathogens causing a clinical syndrome. One oral therapeutic for all cancers of the GI tract. One for all pathogens causing undifferentiated fever. This strategy fundamentally changes how medicine is practiced in the developing world.
Intrinsic Safety Architecture
Every organism we engineer contains multi-layered biocontainment systems that prevent survival outside the human body. These aren't bolted-on safety features — they are woven into the organism's DNA. The result: escape frequencies below one in ten billion, validated by rigorous laboratory testing. Safety is not a feature. It is the architecture.
Commodity-Scale Manufacturing
Our organisms are manufactured using standard fermentation equipment — the same infrastructure that produces beer and bread. No mammalian cell culture. No ultra-cold storage. No specialized biologics facilities. This means production costs 100–1,000x lower than conventional biologics, enabling us to deliver advanced immunotherapy at under one dollar per dose.
Regulatory Intelligence
Our AI regulatory engine analyzes thousands of FDA precedents to identify the fastest path to patients. It automatically generates complete, submission-ready regulatory packages — from Fast Track designation requests to IND filings — ensuring that the speed of our science is matched by the speed of our regulatory strategy.
One Platform. Every Major Disease Category.
Our transformed microbe platform is not a single-disease technology. It is a universal therapeutic architecture with active programs spanning seven disease categories.
Oncology
Multi-antigen oral immunotherapy targeting solid tumors across every body region. Our regional strategy covers all cancers of a body region with a single therapeutic.
Multiple Active ProgramsInfectious Disease
Syndromic multi-pathogen immunotherapy for the developing world. One oral therapeutic covers all organisms causing a clinical syndrome — no diagnostic testing required.
Multiple Active ProgramsAutoimmune Disorders
Precision immune recalibration through engineered mucosal immune modulation. Restoring tolerance rather than suppressing the entire immune system.
Active ResearchGenetic Disorders
Oral delivery of corrective enzymes and therapeutic proteins for hereditary conditions, using engineered microbes as living biofactories.
In DevelopmentNext-Generation Vaccines
Oral, ambient-stable immunization using living microbial platforms. No cold chain, no needles, no trained healthcare workers required. Designed for global deployment.
Active ResearchMicrobiome Therapeutics
Precision engineering of the human microbiome to prevent and treat metabolic, neurological, and inflammatory diseases at their root cause.
In DevelopmentRare Diseases
For the 400 million people worldwide affected by rare diseases, most of whom have no approved treatment. Our low-cost platform makes rare disease therapeutics economically viable for the first time.
Active ResearchAntimicrobial Resistance
A completely new approach to drug-resistant infections: engineered microbes that activate the immune system rather than relying on antibiotics that pathogens learn to defeat.
Active ResearchWhy This Changes Everything
❌ Today's Medicine
- Intravenous infusions in hospital settings
- $100,000–$400,000 per year per patient
- Cold chain storage at −20°C to 8°C
- Single target — tumors escape by mutating one protein
- Available to <15% of the world's population
- Antibiotics driving resistance — creating superbugs
✅ Ablatotech Medicine
- Oral capsule — administered anywhere, by anyone
- Less than $1.00 per dose — commodity manufacturing
- Room temperature stable for 2+ years — no cold chain
- Multi-antigen — prevents immune escape entirely
- Designed for 8 billion people from day one
- Immune activation — no antibiotic resistance
Built for the Developing World. Advanced Enough for Any Patient.
Most biotech companies design for wealthy markets and hope to trickle down. We design for the hardest-to-reach patients first. When a medicine works in a village clinic with no electricity, it works everywhere.
The Future of Medicine Is Being Built Now
We are seeking partners, collaborators, and investors who share our vision of a world where every patient has access to the most advanced medicine science can create.